Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare, inflammatory, and fibrotic diseases. The company's pipeline emphasizes its expertise in cannabinoid-based medicines, with particular interest in conditions such as cystic fibrosis, dermatomyositis, and other inflammatory disorders. Corbus aims to deliver novel treatments targeting underlying disease mechanisms to improve patient outcomes.
Company News
The cannabinoid agonist market is gaining momentum with expanding medical cannabis legalization and growing clinical validation for treating chronic pain, epilepsy, and inflammatory conditions. Over 20 pharmaceutical companies are actively developing cannabinoid agonist drugs with promising pipeline candidates.
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of adult-use markets and adoption of new licensed and regulated markets, both medical and recreational. Key states driving this surge include New York, New Jersey and potentially Florida and Ohio, Bingham says. Influence Of DEA Rescheduling Following the DEA's decision to reclassify cannabis to Schedule III, Bingham predicts this will open up new avenues for medical research and investment. "We expect major medical discoveries within five years," he stated, highlighting the potential for new pharmaceutical applications and a diversification of medical cannabis products. Bingham notes that the rescheduling will be a game-changer for research, allowing scientists to pursue careers studying cannabinoids without risking their careers. "For the last 50 years, studying cannabinoids was a career ender for young scientists. Now, they will be able to pursue it and come up with fascinating discoveries." Economic And Operational Impacts The rescheduling is likely to alleviate financial pressures on cannabis businesses, notably by eliminating certain tax burdens, which Bingham says will "inject much more cash and capital into the industry." This financial liberation is expected to accelerate research and development, particularly in medical cannabis, potentially attracting substantial investment from healthcare and pharmaceutical companies. He also anticipates ...Full story available on Benzinga.com
Corbus Pharmaceuticals (CRBP) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Use these tips to buy penny stocks in December The post Buying Penny Stocks in December? 3 Top Tips to Profit appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Important events on the horizon could push these biotech stocks higher or press them further into the dirt.